iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity